Friday's semiconductor rally lifted the S&P 500 and Nasdaq, but the Dow and Russell fell. Decliners beat advancers 1.78-to-1 on the NYSE and 1.42-to-1 on Nasdaq; this is not broad risk-on confirmation. Reuters close
The official Treasury curve closed at 4.76% for 2Y and 5.01% for 10Y after the Fed raised its target to 3.75%–4.00%. WTI stayed near $100, preserving the inflation/valuation squeeze despite Friday's tech resilience. Treasury · Fed
China held benchmark lending rates unchanged for a 16th month, while U.S. Treasury Secretary Bessent and China's He are due to meet Sunday ahead of the Sept. 24 summit. These are Monday gap risks, not trade signals: Globex was not open at the cutoff. China rates · Sunday meeting
| Asset | Last level | Last move | Session | Read-through |
|---|---|---|---|---|
| S&P 500 | 7,650.50 | +0.17% | Fri. U.S. close | Flat week; resilient headline index. |
| Nasdaq Composite | 26,522.54 | +0.40% | Fri. U.S. close | Semiconductor leadership. |
| Dow / Russell 2000 | 51,682.64 / 2,860.40 | −0.18% / −0.50% | Fri. U.S. close | Cyclicals and breadth lagged. |
| VIX | 14.81 | −4.08% | Fri. close | Low implied fear versus macro risk. |
| U.S. 2Y / 10Y | 4.76% / 5.01% | +9 / +7 bp | Official Fri. curve | High discount-rate hurdle. |
| Dollar index | 100.22 | 0.00% | Fri. close | No fresh weekend FX signal. |
| WTI / Gold | $100.30 / $4,424.90 | −1.58% / +0.57% | Fri. settlement | Oil inflationary; gold retains bid. |
| Nikkei / Hang Seng / Shanghai | 65,018.95 / 24,750.78 / 3,911.87 | +1.38% / +0.60% / +0.94% | Fri. Asia close | Positive close before weekend diplomacy. |
| STOXX 600 / DAX / FTSE | 635.45 / 25,304.06 / 10,659.10 | −1.11% / −1.60% / −1.45% | Fri. Europe close | Europe rejected Thursday relief. |
Price cutoff: Friday Sept. 18 closes/settlements. Yahoo chart API retrieved 08:31 CEST Sunday and cross-checked against CNBC Markets, CNN Markets and Reuters. Treasury yields are the official Sept. 18 par curve. WTI uses the Friday contract/settlement convention cited in the prior report; the active Yahoo contract rolled, so its $96.08 quote is not treated as a weekend move. At 08:30 Italy, U.S. releases and Sunday Globex trading had not begun.
Sunday mode: no executable U.S. equity or index-futures entry exists at this cutoff. Scores are comparative research judgments, not probabilities; Confidence measures evidence quality. Risk is higher when riskier.
NASDAQ · Mega-cap · Medium/high risk · Horizons: 1–4 weeks and 3–12+ months
Thesis/catalyst: Friday's $222.27 close held the $219–220 repair trigger; operating scale and current guidance support long-duration leadership. Counterargument: 5.01% 10Y, export controls and hyperscaler ROI can overwhelm fundamentals.
NYSE · Mega-cap pharma · Medium risk · Horizon: 3–12+ months
Thesis/catalyst: commercial incretin scale plus Sept. 30 TRIUMPH-2 and eloraTZP detail. Counterargument: major success is priced in; safety, access, manufacturing and competition can erode returns.
NASDAQ · High-beta AI infrastructure · Very high risk · Horizons: day trade and 1–4 weeks
Thesis: Friday's $81.36 close remained below the prior $83.35 repair level and the stock lost 8.57% week-on-week while Nasdaq gained. Capital intensity, concentration and 5% long rates remain adverse. Counterargument: contracts, financing or demand headlines can trigger violent rebounds.
NASDAQ · Small-cap/pre-revenue · Extreme binary risk · Horizons: 1–4 weeks; evidence-gated 3–12+ months
Thesis: $28.99 is 9.35% below the prior Friday; Q3 maintenance data remain undated, making pre-data positioning unattractive without tolerance for a binary gap. Counterargument: VANQUISH Phase 3 enrollment and June cash/investments near $502m support runway; strong durability/safety could rerate shares.
| Rank / ticker | Class & horizon | Confirmation | Invalidation / risk | C / R / O |
|---|---|---|---|---|
| 1 AMD NASDAQ, mega-cap, high beta | Bullish watch Day / 1–4 weeks | $559.82; require hold $545–550 and broad semiconductor participation; do not chase gaps. | Close below ~$521; software execution, exports, capex and valuation. History | 73 / 78 / 73 |
| 2 VRT NYSE, AI power/cooling | Reversal watch 1–4 weeks / 3–12 months | $249.39; require close above $250, then $259, with volume. | Loss of $240/234; rates, multiple, orders and acquisition execution. IR | 72 / 76 / 68 |
| 3 IONQ NYSE, speculative quantum | Research-to-revenue 1–4 weeks / 3–12+ months | $39.13; require sustained >$40 and evidence separating quantum growth from acquired SkyWater revenue. | Close below ~$36.8; integration, burn, dilution, roadmap and valuation. Guidance | 74 / 92 / 63 |
| 4 NVO NYSE ADR, large-cap pharma | EASD watch 1–4 weeks / 3–12+ months | $43.24; EASD includes Wegovy pill and next-generation amylin evidence. | Close below $42.7; efficacy/tolerance, pricing, FX, competition and restructuring. Novo archive | 71 / 73 / 63 |
| 5 MU NASDAQ, memory | Earnings watch 1–4 weeks | Sept. 30 fiscal Q4 call is the HBM/memory check; do not anticipate the binary report. | Failed breakout or weak guide; cyclicality, capex, supply and expectations. Micron IR | 75 / 83 / 69 |
Bias: no Sunday trade; Monday favor semis only if NVDA/AMD hold Friday levels and breadth confirms. Biggest risk: weekend geopolitical/oil gap. Invalidation: 10Y extends above 5.01% while Nasdaq breadth turns negative.
Bias: quality growth over leveraged/speculative beta—NVDA conditional above $219–224; CRWV/VKTX avoided until repair. Biggest risk: summit and PCE/jobs repricing. Invalidation: S&P loses the prior week's low with VIX expansion and Russell weakness.
Bias: stage exposure to proven AI and metabolic platforms; keep quantum/clinical biotech small and speculative. Biggest risk: cash economics fail to justify valuation. Invalidation: estimate cuts, financing stress, adverse benefit-risk data or regulatory restrictions.